公开(公告)号：US11230559B2

公开(公告)日：2022-01-25

申请号：US16476172

申请日：2018-01-04

申请人： Hoffmann-La Roche Inc.

发明人： Katja Grosse-Sender ,  Urs Schwitter ,  Frank Stowasser ,  Xuemei Wang ,  Jing Xiong

IPC分类号： C07D513/04 ,  A61P31/20

摘要： The present invention relates to novel solid forms of compound (I) [(1S)-1-[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate and pharmaceutical compositions comprising the solid forms thereof disclosed herein, which may be used as a TLR7 agonist, or for the treatment or prophylaxis of a viral disease in a patient relating to HBV infection or a disease caused by HBV infection.

公开(公告)号：US20230120311A1

公开(公告)日：2023-04-20

申请号：US17946743

申请日：2022-09-16

申请人： Hoffmann-La Roche Inc.

发明人： Kirsten Andrea Graeser ,  Urs Schwitter ,  Frank Stowasser ,  Florence Nicole Antoinette Tixeront ,  Rene Trussardi

IPC分类号： C07D413/12

摘要： Described herein are amorphous and crystalline forms of pharmaceutically acceptable salts of the TAAR1 agonist 5-ethyl-4-methyl-N-[4-[(2S) morpholin-2-yl]phenyl]-1H-pyrazole-3-carboxamide. Also described are pharmaceutical compositions suitable for administration to a mammal that include the TAAR1 agonist, and methods of using the TAAR1 agonist, alone and in combination with other compounds, for treating diseases or conditions that are associated with TAAR1 activity.